Pharming Group (NASDAQ:PHAR) was the target of a large increase in short interest during the month of September. As of September 30th, there was short interest totalling 900 shares, an increase of 350.0% from the September 15th total of 200 shares. Based on an average trading volume of 900 shares, the short-interest ratio is currently 1.0 days.
Separately, Zacks Investment Research lowered Pharming Group from a “hold” rating to a “sell” rating in a research report on Thursday, August 19th.
NASDAQ PHAR opened at $9.02 on Thursday. The firm has a market cap of $582.80 million and a PE ratio of 15.55. The company has a debt-to-equity ratio of 0.73, a current ratio of 5.25 and a quick ratio of 4.74. The stock’s 50 day simple moving average is $10.10 and its 200 day simple moving average is $11.44. Pharming Group has a one year low of $9.02 and a one year high of $21.99.
Institutional investors and hedge funds have recently made changes to their positions in the business. UBS Group AG boosted its position in Pharming Group by 173.8% in the 1st quarter. UBS Group AG now owns 2,508 shares of the company’s stock valued at $32,000 after buying an additional 1,592 shares during the last quarter. Morgan Stanley boosted its position in Pharming Group by 5,208.3% in the 2nd quarter. Morgan Stanley now owns 2,548 shares of the company’s stock valued at $29,000 after buying an additional 2,500 shares during the last quarter. Finally, Cowen Prime Advisors LLC bought a new position in shares of Pharming Group in the 2nd quarter worth $71,000. Hedge funds and other institutional investors own 0.31% of the company’s stock.
Pharming Group Company Profile
Pharming Group N.V., a specialty pharmaceutical company, develops products for the treatment of rare diseases and unmet medical needs in the United States, Europe, and internationally. The company's lead product is Ruconest, a recombinant human C1 esterase inhibitor that is used for the treatment of acute hereditary angioedema.
Further Reading: Moving Average (MA)
Receive News & Ratings for Pharming Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pharming Group and related companies with MarketBeat.com's FREE daily email newsletter.